- Home
- IMMR vs NTHI Comparison
IMMR vs NTHI Comparison
Compare IMMR & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMMR | NTHI |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.4M | 195.5M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | IMMR | NTHI |
|---|---|---|
| Price | $6.82 | $9.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $12.25 | N/A |
| AVG Volume (30 Days) | ★ 547.4K | 81.6K |
| Earning Date | 09-11-2025 | 11-14-2025 |
| Dividend Yield | ★ 2.64% | N/A |
| EPS Growth | ★ 57.07 | N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $163,133,000.00 | $59,990.00 |
| Revenue This Year | $988.71 | N/A |
| Revenue Next Year | $109.72 | N/A |
| P/E Ratio | $3.34 | ★ N/A |
| Revenue Growth | ★ 338.21 | N/A |
| 52 Week Low | $5.65 | $3.20 |
| 52 Week High | $10.72 | $25.00 |
Technical Indicators
Market Signals| Indicator | IMMR | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 53.39 | 51.29 |
| Support Level | $6.65 | $8.46 |
| Resistance Level | $7.24 | $9.42 |
| Average True Range (ATR) | 0.32 | 0.98 |
| MACD | 0.07 | 0.20 |
| Stochastic Oscillator | 71.28 | 84.17 |
Price Performance
Historical ComparisonAbout IMMR Immersion Corporation
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).